Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy.
Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.
McCluggage
W G
WG
Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland.
Bryson
C
C
Lamki
H
H
Boyle
D D
DD
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D001943:Breast Neoplasms / Q000188:drug therapy; D018269:Carcinoma, Endometrioid / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000473:pathology; D004715:Endometriosis / Q000473:pathology*; D004965:Estrogen Antagonists / Q000009:adverse effects; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D013629:Tamoxifen / Q000009:adverse effects*
D004965:Estrogen Antagonists; D013629:Tamoxifen